 |
|
Isolated Limb Perfusion of an Irradiated Foot With Tumor Necrosis Factor, Interferon, and Melphalan
Robert J. van Ginkel, MD;
Harald J. Hoekstra, MD, PhD;
Alex M. M. Eggermont, MD, PhD;
Elisabeth Pras, MD;
Heimen Schraffordt Koops, MD, PhD
Arch Surg. 1996;131(6):672-674.
Abstract
A 57-year-old woman presented with the second recurrence of a high-grade malignant fibrous histiocytoma of the right foot, following previous local resection plus curative adjuvant radiotherapy. The first recurrence of the lesion was treated by isolated limb perfusion with cisplatin; the second recurrence was treated by isolated limb perfusion with tumor necrosis factor, interferon, and melphalan. The tumor and the area that had been irradiated showed a bluish color a few hours after tumor necrosis factor perfusion. Amputation of the right foot and leg below the knee had to be performed because of severe necrosis. (Arch Surg. 1996;131:672-674)
Author Affiliations
From the Departments of Surgical Oncology (Drs van Ginkel, Hoekstra, and Schraffordt Koops) and Radiotherapy (Dr Pras), Groningen University Hospital, Groningen, and the Dr Daniël den Hoed Cancer Center, Rotterdam (Dr Eggermont), the Netherlands.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Isolated Limb Perfusion with Tumor Necrosis Factor Alpha and Melphalan for Locally Advanced Soft Tissue Sarcoma: Three Time Periods at Risk for Amputation
van Ginkel et al.
Ann. Surg. Oncol. 2007;14:1499-1506.
ABSTRACT
| FULL TEXT
Isolated Limb Perfusions With Tumor Necrosis Factor and Melphalan for Locally Recurrent Soft Tissue Sarcoma in Previously Irradiated Limbs
Lans et al.
Ann. Surg. Oncol. 2005;12:406-411.
ABSTRACT
| FULL TEXT
|
